April 3 (Reuters) - Two doses of Eli Lilly's ( LLY )

weight-loss drug, Zepbound, would be available in limited

amounts through end of April due to increased demand, the U.S.

health regulator's website showed.

The Food and Drug Administration noted limited availability

of 5 and 12.5 milligram doses, while 2.5, 7.5, 10 and 15

milligram doses were listed as available.

The regulator on Tuesday notified tight supply of certain

doses of Lilly's diabetes drug, Mounjaro, through April.

Lilly did not immediately respond to a Reuters request for

comment.